Evidence map›Paper›PMID 41436261›Full record

ArticleBMJ open2025

Safety of COVID-19 vaccines among pregnant individuals in Quebec, Canada: a population-based retrospective cohort study from the Canadian Immunization Research Network.

Marilou Kiely, Ella Diendere, Isaora Dialahy, Gentiane Perrault-Sullivan, Nicholas Brousseau, Shu Qin Wei, Denis Talbot, Amélie Boutin, Caroline Quach, Sarah Jorgensen and 1 more

Abstract read
In one paragraph

Article in BMJ open, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Marilou KielyMédecine sociale et préventive, Université Laval Faculté de Médecine, Québec City, Quebec, Canada marilou.kiely@fmed.qc.ca.ORCID http://orcid.org/0000-0002-0235-3630
Ella DiendereInstitut national de santé publique du Québec, Québec City, Quebec, Canada.
Isaora DialahyQuebec National Institute of Public Health, Quebec City, Quebec, Canada.
Gentiane Perrault-SullivanInstitut national de santé publique du Québec, Québec City, Quebec, Canada.
Nicholas BrousseauCentre de recherche du CHU de Québec-Université Laval Site CHUL, Québec City, Quebec, Canada.ORCID http://orcid.org/0000-0001-6042-3177
Shu Qin WeiOriginElle Fertility Clinic and Women's Health Center, Montreal, Quebec, Canada.
Denis TalbotMédecine sociale et préventive, Université Laval Faculté de Médecine, Québec City, Quebec, Canada.ORCID http://orcid.org/0000-0003-0431-3314
Amélie BoutinCentre de recherche du CHU de Québec-Université Laval Site CHUL, Québec City, Quebec, Canada.
Caroline QuachDepartment of Epidemiology, Biostatistics and Occupational Health, University of Montreal, Montreal, Quebec, Canada.
Sarah JorgensenMarshfield Clinic Research Institute, Marshfield, Wisconsin, USA.
Isabelle BoucoiranCHU Sainte-Justine, Montreal, Quebec, Canada.ORCID http://orcid.org/0000-0001-9545-6024

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

objectiveTo estimate the association between maternal COVID-19 vaccination during pregnancy and adverse neonatal and maternal outcomes.

designPopulation-based retrospective cohort study using a hospitalisation database linked with other health administrative databases.

settingProvince of Quebec, Canada, from 1 May 2021 to 30 June 2023.

participantsAll singleton pregnancies resulting in a live birth or stillbirth at ≥20 weeks of gestation, excluding those with a conception date <42 weeks before the end of the study period. PRIMARY OUTCOME MEASURES: We used robust Poisson regression models to estimate adjusted risk ratios (aRRs) for chorioamnionitis, postpartum haemorrhage, caesarean delivery, preterm birth, very preterm birth, small for gestational age (SGA), maternal and neonatal admission to intensive care unit (ICU, NICU) and severe neonatal morbidity. We used a Cox regression model with a time-varying exposure variable to estimate adjusted HRs (aHRs) for stillbirth. Propensity score weighting was used to adjust for potential confounding.

resultsAmong 140 073 singleton pregnancies resulting in live birth or stillbirth, 61 282 individuals (43.8%) received at least one dose of messenger RNA COVID-19 vaccine during pregnancy. Vaccination during pregnancy was not associated with an increased risk of chorioamnionitis (aRR 0.99, 95% CI 0.95 to 1.04), postpartum haemorrhage (aRR 1.03, 95% CI 0.99 to 1.06), very preterm birth (aRR 1.04, 95% CI 0.89 to 1.21) and stillbirth (aHR 1.14, 95% CI 0.94 to 1.39). Vaccination during pregnancy was significantly associated with a reduced risk of caesarean delivery (aRR 0.94, 95% CI 0.92 to 0.96), maternal ICU admission (aRR 0.80, 95% CI 0.65 to 0.98), SGA (aRR 0.94, 95% CI 0.91 to 0.98), NICU admission (aRR 0.91, 95% CI 0.85 to 0.96), preterm birth (aRR 0.94, 95% CI 0.90 to 0.99) and severe neonatal morbidity (aRR 0.91, 95% CI 0.85 to 0.98).

conclusionsOur findings suggest that COVID-19 vaccination during pregnancy was not associated with an increased risk of adverse outcomes. Ongoing surveillance of the safety of maternal COVID-19 vaccination is essential as doses continue to be recommended for this group.

Indexed as

COVID-19COVID-19 VaccinesPregnancy Complications, InfectiousAdultChorioamnionitisFemaleHumansInfant, NewbornInfant, Small for Gestational AgePregnancyPregnancy OutcomePremature BirthQuebecRetrospective StudiesSARS-CoV-2StillbirthCOVID-19 VaccinesCOVID-19Immunization ProgramsINFECTIOUS DISEASESPregnancy

Identifiers

PMID41436261
PMCPMC12730766

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.